TY - JOUR
T1 - Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease
T2 - Results from the VedoKids study
AU - D'Arcangelo, Giulia
AU - Turner, Dan
AU - Ledder, Oren
AU - Orlanski-Meyer, Esther
AU - Broide, Efrat
AU - Granot, Maya
AU - Matar, Manar
AU - Hussey, Seamus
AU - Yerushalmy-Feler, Anat
AU - Norden, Christoph
AU - Miele, Erasmo
AU - Aloi, Marina
N1 - Publisher Copyright:
© 2025 The Author(s). Journal of Pediatric Gastroenterology and Nutrition published by Wiley Periodicals LLC on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
PY - 2025
Y1 - 2025
N2 - Extraintestinal manifestations (EIMs) manifest in 6%-47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged 0–18 years) with IBD treated with vedolizumab and followed through 54 weeks. EIMs were identified in 18/142 (12.6%) children at baseline; 56% of these cases were articular EIMs; the EIMs resolved in 89% within 18 months. Concomitant medications were administered in 72% of EIM cases, most of which were ongoing at the time of vedolizumab initiation. Of the 124 children without EIMs, five (4%) developed EIMs during follow up: three arthritis, two cutaneous manifestations. The presence of EIMs did not affect the durability of vedolizumab treatment. In conclusion, most EIMs in children with IBD resolved with vedolizumab treatment, but almost half received concomitant medications. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02862132. https://clinicaltrials.gov/study/NCT02862132?term=NCT02862132&rank=1.
AB - Extraintestinal manifestations (EIMs) manifest in 6%-47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged 0–18 years) with IBD treated with vedolizumab and followed through 54 weeks. EIMs were identified in 18/142 (12.6%) children at baseline; 56% of these cases were articular EIMs; the EIMs resolved in 89% within 18 months. Concomitant medications were administered in 72% of EIM cases, most of which were ongoing at the time of vedolizumab initiation. Of the 124 children without EIMs, five (4%) developed EIMs during follow up: three arthritis, two cutaneous manifestations. The presence of EIMs did not affect the durability of vedolizumab treatment. In conclusion, most EIMs in children with IBD resolved with vedolizumab treatment, but almost half received concomitant medications. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02862132. https://clinicaltrials.gov/study/NCT02862132?term=NCT02862132&rank=1.
KW - biologic therapy
KW - children
KW - prospective data
KW - real-world evidence
KW - treatment outcomes
UR - https://www.scopus.com/pages/publications/105022183278
U2 - 10.1002/jpn3.70276
DO - 10.1002/jpn3.70276
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 41251034
AN - SCOPUS:105022183278
SN - 0277-2116
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
ER -